JPWO2021079958A1 - - Google Patents
Info
- Publication number
- JPWO2021079958A1 JPWO2021079958A1 JP2021553541A JP2021553541A JPWO2021079958A1 JP WO2021079958 A1 JPWO2021079958 A1 JP WO2021079958A1 JP 2021553541 A JP2021553541 A JP 2021553541A JP 2021553541 A JP2021553541 A JP 2021553541A JP WO2021079958 A1 JPWO2021079958 A1 JP WO2021079958A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019194717 | 2019-10-25 | ||
| PCT/JP2020/039802 WO2021079958A1 (ja) | 2019-10-25 | 2020-10-23 | 抗garp抗体と免疫調節剤の組み合わせ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2021079958A1 true JPWO2021079958A1 (cg-RX-API-DMAC7.html) | 2021-04-29 |
Family
ID=75620128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553541A Pending JPWO2021079958A1 (cg-RX-API-DMAC7.html) | 2019-10-25 | 2020-10-23 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240190961A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4049675A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2021079958A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220088425A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114630679A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022007632A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3155172A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI887285B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021079958A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7734856B2 (ja) * | 2021-09-30 | 2025-09-05 | ▲貝▼▲達▼▲薬▼▲業▼股▲フン▼有限公司 | 二重特異性抗体及びその使用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012500006A (ja) * | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−3(lag−3)へ結合するヒト抗体およびその使用 |
| WO2016125017A1 (en) * | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| WO2017051888A1 (ja) * | 2015-09-24 | 2017-03-30 | 第一三共株式会社 | 抗garp抗体 |
| WO2018181425A1 (ja) * | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
| WO2018222718A1 (en) * | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| EP1506285B1 (en) | 2001-11-01 | 2010-12-08 | Uab Research Foundation | Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents |
| EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| EP2832747A1 (en) * | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
| AU2014298373B2 (en) * | 2013-08-01 | 2019-12-05 | Ludwig Institute For Cancer Research Ltd | Anti-GARP protein and uses thereof |
| WO2017173091A1 (en) * | 2016-03-30 | 2017-10-05 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination |
| EP3484499A4 (en) * | 2016-07-14 | 2020-05-13 | Scholar Rock, Inc. | TGFB ANTIBODIES, METHODS AND USE |
| JP2020519579A (ja) * | 2017-05-09 | 2020-07-02 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | Lrrc33阻害剤およびその使用 |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US20230192867A1 (en) * | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
-
2020
- 2020-10-23 CN CN202080074466.XA patent/CN114630679A/zh active Pending
- 2020-10-23 CA CA3155172A patent/CA3155172A1/en active Pending
- 2020-10-23 US US17/769,600 patent/US20240190961A1/en active Pending
- 2020-10-23 KR KR1020227013131A patent/KR20220088425A/ko active Pending
- 2020-10-23 TW TW109136828A patent/TWI887285B/zh active
- 2020-10-23 EP EP20879730.8A patent/EP4049675A4/en active Pending
- 2020-10-23 WO PCT/JP2020/039802 patent/WO2021079958A1/ja not_active Ceased
- 2020-10-23 BR BR112022007632A patent/BR112022007632A2/pt unknown
- 2020-10-23 JP JP2021553541A patent/JPWO2021079958A1/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012500006A (ja) * | 2008-08-11 | 2012-01-05 | メダレックス インコーポレーティッド | リンパ球活性化遺伝子−3(lag−3)へ結合するヒト抗体およびその使用 |
| WO2016125017A1 (en) * | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
| WO2017051888A1 (ja) * | 2015-09-24 | 2017-03-30 | 第一三共株式会社 | 抗garp抗体 |
| WO2018181425A1 (ja) * | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
| WO2018222718A1 (en) * | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
Non-Patent Citations (2)
| Title |
|---|
| SCI. TRANSL. MED., vol. vol.7, issue 284, JPN6025013276, 2015, pages 56 - 1, ISSN: 0005567448 * |
| VARGAS, FA., ET AL.: "Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Block", IMMUNITY, vol. vol.46, issue 4, JPN6020049320, 2017, pages 577 - 586, ISSN: 0005742550 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114630679A (zh) | 2022-06-14 |
| TWI887285B (zh) | 2025-06-21 |
| CA3155172A1 (en) | 2021-04-29 |
| EP4049675A1 (en) | 2022-08-31 |
| US20240190961A1 (en) | 2024-06-13 |
| TW202128761A (zh) | 2021-08-01 |
| BR112022007632A2 (pt) | 2022-07-12 |
| WO2021079958A1 (ja) | 2021-04-29 |
| KR20220088425A (ko) | 2022-06-27 |
| EP4049675A4 (en) | 2023-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019017762A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016141A2 (cg-RX-API-DMAC7.html) | ||
| AU2020104490A5 (cg-RX-API-DMAC7.html) | ||
| BR112019016138A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016142A2 (cg-RX-API-DMAC7.html) | ||
| BR112021012348A2 (cg-RX-API-DMAC7.html) | ||
| BR112021013128A2 (cg-RX-API-DMAC7.html) | ||
| BR112019016136A2 (cg-RX-API-DMAC7.html) | ||
| BR102019023359A2 (cg-RX-API-DMAC7.html) | ||
| BR102020025141B1 (pt) | Máquina elétrica girante eletronicamente comutada | |
| BR102020020816B1 (pt) | Veículo, e, método para controlar o movimento de ar através de um veículo com uma ventoinha do veículo | |
| BR102020018650B1 (pt) | Método para preparar óxido de cálcio usando um forno pré- aquecedor de suspensão de múltiplos estágios | |
| BR102020017390B1 (pt) | Bomba multifásica | |
| BR102020011722B1 (pt) | Porta de tela para um pacote de radiadores | |
| BR102020005860B1 (pt) | Controle de obstrução para um implemento agrícola | |
| BR112021012379B1 (pt) | Material de aço adequado para uso em ambiente ácido | |
| BR112021012064B1 (pt) | Sistema e método de previsão de risco de ataque de insetos | |
| BR112021013352B1 (pt) | Processo e dispositivo para endireitar arame ou material de fita | |
| BR112021010564B1 (pt) | Sistema de armadilha para animais e método de monitoramento do mesmo | |
| BR102020000355B1 (pt) | Embreagem que tem dois estágios para aplicar torque variado entre um eixo de entrada e um eixo de saída | |
| BR102019027339B1 (pt) | Sistema de aspersão de água e difusor de sistema de aspersão de água | |
| BR102019026542B1 (pt) | Sistema para detectar e controlar a posição de spoiler de asa de aeronave | |
| BR102019026215B1 (pt) | Sinalizador acústico | |
| BR102019026293B1 (pt) | Sistema de aeronave, e, método para transmitir energia de um primeiro componente para um segundo componente | |
| BR102019026001B1 (pt) | Disposição de controle de atuador, e, disposição de controle de spoiler para uma aeronave |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240925 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20241101 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250124 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250408 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250529 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250805 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260401 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260714 |